# EDGAR Filing Document

**Accession Number:** 0002082085
**File Stem:** 0001140361-26-008118
**Filing Date:** 2026-3
**Character Count:** 10219
**Document Hash:** 773c89951382da7667e730013cf823f4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-008118.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001140361-26-008118

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260303

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Enrietti Andrew
- **CENTRAL INDEX KEY:** 0002082085

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39695
- **FILM NUMBER:** 26727981

**MAIL ADDRESS:**
- **STREET 1:** 1000 MYLAN BOULEVARD
- **CITY:** CANONSBURG
- **STATE:** PA
- **ZIP:** 15317
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Viatris Inc
- **CENTRAL INDEX KEY:** 0001792044
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 834364296
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 MYLAN BOULEVARD
- **CITY:** CANONSBURG
- **STATE:** PA
- **ZIP:** 15317
- **BUSINESS PHONE:** (724) 514-1465

**MAIL ADDRESS:**
- **STREET 1:** 1000 MYLAN BOULEVARD
- **CITY:** CANONSBURG
- **STATE:** PA
- **ZIP:** 15317

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Upjohn Inc
- **DATE OF NAME CHANGE:** 20191023

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Enrietti Andrew<br><sub>(Last) (First) (Middle)</sub><br>1000 MYLAN BOULEVARD<br><sub>(Street)</sub><br>CANONSBURG, PA 15317<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-03 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_See Remarks_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Viatris Inc [ VTRS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-03-03 |  | X |  | 11531 | A | $0 | 141531 | D |  |
| Common Stock | 2026-03-03 |  | F |  | 5094<sup>(1)</sup> | D | $14.89 | 136437 | D |  |
| Common Stock | 2026-03-03 |  | X |  | 1709<sup>(2)</sup> | A | $0 | 138146 | D |  |
| Common Stock | 2026-03-03 |  | F |  | 744<sup>(3)</sup> | D | $14.89 | 137402 | D |  |
| Common Stock | 2026-03-03 |  | M |  | 110630 | A | $0 | 248032 | D |  |
| Common Stock | 2026-03-03 |  | F |  | 48113<sup>(4)</sup> | D | $14.89 | 199919 | D |  |
| Common Stock | 2026-03-04 |  | X |  | 13568 | A | $0 | 213487 | D |  |
| Common Stock | 2026-03-04 |  | F |  | 5901<sup>(5)</sup> | D | $14.71 | 207586 | D |  |
| Common Stock | 2026-03-04 |  | X |  | 1279<sup>(6)</sup> | A | $0 | 208865 | D |  |
| Common Stock | 2026-03-04 |  | F |  | 557<sup>(7)</sup> | D | $14.71 | 208308 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | $0 | 2026-03-03 |  | X |  |  | 11531 | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 11531 | $0 | 0 | D |  |
| Dividend Equivalent Units | $0 | 2026-03-03 |  | X |  |  | 1708.1145<sup>(9)</sup> | <sup>(10)</sup> | <sup>(10)</sup> | Common Stock | 1708.1145 | $0 | 0 | D |  |
| Performance Restricted Stock Units <sup>(11)</sup> | $0 | 2026-03-03 |  | A |  | 110630<sup>(11)</sup> |  | <sup>(12)</sup> | <sup>(12)</sup> | Common Stock | 110630 | $0 | 110630 | D |  |
| Performance Restricted Stock Units | $0 | 2026-03-03 |  | M |  |  | 110630 | <sup>(12)</sup> | <sup>(12)</sup> | Common Stock | 110630 | $0 | 0 | D |  |
| Restricted Stock Units | $0 | 2026-03-04 |  | X |  |  | 13568 | <sup>(13)</sup> | <sup>(13)</sup> | Common Stock | 13568 | $0 | 13569 | D |  |
| Dividend Equivalent Units | $0 | 2026-03-04 |  | X |  |  | 1278.2776<sup>(9)</sup> | <sup>(14)</sup> | <sup>(14)</sup> | Common Stock | 1278.2776 | $0 | 1278<sup>(9)</sup> | D |  |

---

### Footnotes:

(1) Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 3, 2023.

(2) Fractional shares have been rounded up in connection with the settlement described in footnote 10 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.

(3) Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 3, 2023.

(4) Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of the performance restricted stock units (PRSUs) granted on March 3, 2023.

(5) Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the RSUs granted on March 4, 2024.

(6) Fractional shares have been rounded up in connection with the settlement described in footnote 14 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.

(7) Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the DEUs that accrued with respect to the RSUs previously granted on March 4, 2024.

(8) Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris).  11,531 of the RSUs granted on March 3, 2023 vested on March 3, 2024, 11,530 vested on March 3, 2025, and 11,531 vested on March 3, 2026.

(9) Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.

(10) Represents DEUs that accrued with respect to the RSUs previously granted on March 3, 2023 and vest on the same schedule as the underlying RSUs.

(11) Amount includes DEUs that accrued with respect to the PRSUs previously granted on March 3, 2023 and vest on the same schedule as the underlying PRSUs. Fractional shares with respect to such DEUs were rounded up pursuant to the terms of the PRSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.

(12) Each PRSU represents the right to receive one share of common stock of Viatris.  The PRSUs were initially granted on March 3, 2023, subject to the attainment of previously established three-year performance goals and a vesting period. The PRSUs vested on March 3, 2026.

(13) Each RSU represents the right to receive one share of common stock of Viatris. 13,569 of the RSUs granted on March 4, 2024 vested on March 4, 2025, 13,568 vested on March 4, 2026, and 13,569 will vest on March 4, 2027.

(14) Represents DEUs that accrued with respect to the RSUs previously granted on March 4, 2024 and vest on the same schedule as the underlying RSUs.

**Remarks:**
Chief Administrative and Transformation Officer

**Signature:** /s/ Kevin Macikowski, by power of attorney  
**Date:** 2026-03-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**